The eBay logo at San Jose, California, headquaters (Justin Sullivan/Getty Images)

EBay beats Q4 earnings estimates, but investors hit the sell button on lukewarm guidance

EBay shares sank after the second-largest online marketplace delivered a lukewarm first-quarter forecast.

2/26/25 5:20PM

Shares of eBay sank 8% in after-hours trading after the giant online marketplace delivered a lukewarm forecast for the first quarter. On paper, eBay’s fourth quarter looked solid: adjusted earnings per share came in at $1.25, topping Wall Street expectations of $1.20. Meanwhile, revenue grew a modest 1% to $2.58 billion, but was still in line with estimates. Gross merchandise volume — a key metric for the company — also rose 4% to $19.3 billion, surpassing analyst expectations of $19.0 billion.

But a strong past performance wasn’t enough to ease fears of what’s ahead. EBay’s revenue forecast for the current quarter came in between $2.52 billion and $2.56 billion, falling short of analysts’ $2.59 billion projection.

Investors have watched eBay’s marketplace closely as it deals with slowing GMV growth and shrinking margins. EBay has been navigating a shift in consumer spending as demand cools for collectibles and refurbished goods. Before the post-earnings drop, eBay’s stock had risen about 57% in the past year.

Claire Yubin Oh15m

Globalstar surges after FT reports that Amazon is in talks to buy the satellite group

Globalstar is up 11% in premarket trading on Thursday on reports that Amazon is in talks to buy the satellite company, in a push to take on Elon Musk's SpaceX. The two companies are currently negotiating the details of a potential deal after lengthy talks, the Financial Times reported, citing people familiar with the matter.

Amazon has ambitions to compete with Elon Musk's SpaceX to provide satellite-based internet access anywhere on the planet — a market which is dominated by Starlink at the moment and is a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing on its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation with has some 10,000 active satellites.

But Amazon’s not the only big tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, per Bloomberg last October.

Globalstar's stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

Amazon in talks to buy $9bn satellite group Globalstar in bid to rival Elon Musk’s Starlink

Globalstar's stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

J. Edward Moreno16m

FDA clarifies stricter stance on GLP-1 compounding: Reuters

The Food and Drug Administration reiterated its increasingly strict stance on compounded versions of GLP-1s, Reuters reported Wednesday.

The FDA said that, outside of drug shortages, “routine production” of copycat drugs is not allowed. Producing the compounded versions could now “prompt enforcement action,” Reuters reported.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

US FDA clarifies policies on compounding of GLP-1 medicines

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Luke Kawa

Oil spikes, equity futures retreat as President Trump commits to hitting Iran “extremely hard” over the next two to three weeks

The ongoing war threatens to bring about an even more pronounced disruption to energy supplies, with negative ramifications for economic activity and financial markets.